ResearchMoz

Global Meter Data Management Market 2012 - 2016

Technavio
Published Date » 2013-09-20
No. Of Pages » 60
   
 TechNavio's analysts forecast the Global Meter Data Management market to grow at a CAGR of 16.55 percent over the period 2012-2016. One of the key factors contributing to this market growth is the need to reduce the incidences of electricity theft. The Global Meter Data Management market has also been witnessing an increasing support from regulatory authorities. However, data management issues could pose a challenge to the growth of this market.  
   
 TechNavio's report, the Global Meter Data Management Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the markets in the Americas and the EMEA and the APAC regions; it also covers the Global Meter Data Management market landscape and its growth...
TABLE OF CONTENT

1. Executive Summary

2. Scope of the Report
2.1 Market Overview
2.2 Product Offerings

3. Market Research Methodology
3.1 Market Research Process
3.2 Research Design
3.3 Research Methodology

4. List of Abbreviations

5. Introduction

6. Smart Grid IT Spending in Various Segments
6.1 Smart Grid IT Spending Segments
6.1.1 Smart Grid IT Spending in Services Segment
6.1.2 Smart Grid IT Spending in Hardware Segment
6.1.3 Smart Grid IT Spending in Software Segment

7. Market Landscape
7.1 Market Overview
7.2 Meter Data Management Advantages
7.3 Market Size and Forecast
7.4 Five Forces Analysis

8. Geographical Segmentation
8.1 Global Meter Data Management Market by Geographical Segmentation

9. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Market New Entrants
16.1.2 Mergers and Acquisitions
16.2 Major Meter Data Management Vendors
16.3 Other Meter Data Management Vendors
16.4 System Integrators

17. Key Vendor Analysis
17.1 Elster Group SE
Business Overview
Key Information
Business Segmentation
17.1.1 SWOT Analysis
17.2 Itron Inc.
Business Overview
Business Segmentation
Key Information
SWOT Analysis
17.3 Landis+Gyr AG
Business Overview
Key Information
SWOT Analysis
17.4 Oracle Corp.
Business Overview
Key Information
Business Segmentation
17.4.1 SWOT Analysis
17.5 Siemens AG
Business Overview
Reporting Structure
Employee Structure by Region
R&D Facilities by Region
Revenue Generation
Key Information
SWOT Analysis

18. Other Reports in this Series

List of Tables


List of Figures


Exhibit 1: Market Research Methodology
Exhibit 2: Smart Grid IT Spending Segments
Exhibit 3: Smart Grid IT Spending in the Services Segment 2012
Exhibit 4: Smart Grid IT Spending in the Services Segment 2012
Exhibit 5: Smart Grid IT Spending in the Software Segment 2012
Exhibit 6: Change in Business Process
Exhibit 7: Global Meter Data Management Market 2012-2016 (US$ million)
Exhibit 8: Global Meter Data Management Market by Geographical Segmentation 2012
Exhibit 9: Competitive Landscape of Global Meter Data Management Market 2012
Exhibit 10: Business Segmentation of Elster Group SE. 2011 (percent)
Exhibit 11: Itron Inc. Business Segmentation and End-users
Exhibit 12: Business Segmentation of Oracle Corp.
Exhibit 13: Siemens AG Reporting Structure 2012
Exhibit 14: Siemens AG Employee Structure by Region 2012
Exhibit 15: Siemens AG R&D Facilities by Region 2012
Exhibit 16: Siemens AG Revenue by Region 2012
Exhibit 17: Siemens AG Revenue by Country 2012
Exhibit 18: Siemens AG Revenue by Segment 2012
Exhibit 19: Siemens AG Revenue by Business within Segments 2012

Upcoming Reports:

Generic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
The generic drugs industry comprises of the manufacture and marketing of certain drugs which have the same active ingredients as the brand-name drugs manufactured by any pharmaceutical company. The major benefit of generic drugs is that the cost of such drugs is much less than that of branded drugs. Generic drugs come under the same governing framework as that of the brand-name drugs. The rationale behind generic drugs is that the patented drugs generally have a patent life of 20 years. However, the patent life of such drugs begins from the clinical trials and thus their commercial...
Biologics Market - G7 Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
By - Transparency Market Research
With an increase in the number of clinical trials in the past 5 years, the market for biologics is expected to witness a high growth during the coming years. Monoclonal antibodies, vaccines and therapeutic proteins will contribute significantly to the growth in the biologics market. The global biologics market is estimated to reach $176.4 billion by the end of 2012 and expected to grow at an annual compound growth rate of more than 9.5%. In the U.S. the market will witness significant growth, due to a resolution passed by the U.S. lawmakers in 2010; There is increasing...
Poland: lettuce market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the lettuce market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the lettuce market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate overview of the main...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Loss recorded due to heavy investments carried out by Amazon
Jul 25, 2014  
Amazon.com Inc has been investing in newer businesses like consumer electronics and digital content, due to which it has been running into losses for some time now. The loss recorded in the second quarter was by far the highest. In 2014, the stock prices have dropped by 10% with reduced investor confidence in the long term growth investments. The shares of this US based online retailer...
High-sodium Diet Increases Risks of Cardiovascular Diseases in Type 2 Diabetics
Jul 24, 2014  
A new research has found relation between the amount of salt in diet of diabetics and their chances of suffering from cardiovascular diseases. The research has stated that diabetics who have a high-salt diet are on a higher risk of having a chronic heart disease as compared to the ones who eat less salt.  The study’s findings provide evidences that support the benefits of a...
Strides Arcolab Bags USFDA Approval for Transplant Drug
Jul 24, 2014  
Indian pharmaceutical company Strides Arcolab has received the approval of the USFDA to sell its transplant drug Tacrolimus in the US market. The capsule is an immune-suppressant that is used for preventing organ rejection that may occur in transplant surgeries of organs such as kidneys, heart or liver in some patients.  USFDA has allowed the sale of the tablets in 5 mg, 1 mg and 0.5...
Chinese manufacturing gauge gets a hike after months
Jul 24, 2014  
China manufacturing gauge has climbed to its 18-month high this month, which has boosted the government’s chance of meeting the target for economic growth set for 2014, by a percentage of 7.5. The Purchasing Managers Index (PMI) preliminary from Markit Economics and HSBC Holdings Plc was at 52.0 and its has topped the 51.0 median estimate. These numbers indicate an above 50 mark. The...
Paracetamol doesn’t speed recovery or reduce low back pain: Study
Jul 24, 2014  
Paracetamol, which has long since been prescribed as a painkiller for severe low back pain, is no better than placebo; findings of a recent study in Australia have shown. The trial that was published on Thursday found that the universally recommended painkiller neither speeds recovery nor reduces the pain. Paracetamol is merely acts as a placebo or dummy pills doing nothing to ease the...